News Center

5-Fluorouracil (5-FU) is a uracil analog and inhibitor of DNA synthesis, exhibiting antitumor activity by affecting pyrimidine synthesis through thymidylate synthase inhibition; it induces apoptosis and autophagy.

Join TargetMol at DOT booth #110 to explore our latest offerings and innovations in drug discovery and chemical biology. Visit TargetMol at SFN booth #1012 to discover our cutting-edge products and solutions tailored for neuroscience research.

Trametinib is a highly selective MEK inhibitor that blocks the proliferation of tumor cells by inhibiting the key enzymes MEK1/2 in the RAS-RAF-MEK-ERK signaling pathway. It can also activate autophagy and induce apoptosis, playing a crucial role in the treatment of cancers with BRAF mutations. Trametinib is commonly used in research related to the treatment of unresectable or metastatic melanoma with BRAF V600E or V600K mutations.

TargetMol will be participating in The 83rd Annual Meeting of the Japanese Cancer Association (JCA), which will take place from September 19-21, 2024, in Fukuoka, Japan. This prestigious conference brings together leading researchers, clinicians, and industry professionals to explore the latest advancements in cancer research and treatment. Date: September 19 (thu)-21(sat), 2024 Location: Fukuoka International Congress Center, Marine Messe Fukuoka Hall B (マリンメッセ福岡Ｂ館, 〒812-0031 福岡県福岡市博多区沖浜町2−1) Theme: Cancer Research for Perfect Cure TargetMol Booth: No.1 Conference Link: https://site.convention.co.jp/jca2024/ At this year’s event, TargetMol will showcase our extensive range of cutting-edge small molecules and bioactive compounds that support cancer research, drug discovery, and development.We invite all attendees to visit us at Booth No. 1 to learn more about our offerings and explore potential collaborations.

Necrostatin-1 (Nec-1)(Product No. T1847, CAS 4311-88-0) is a necroptosis inhibitor targeting RIPK1 and also an IDO inhibitor. Necrostatin-1 consists of a benzene ring, an aminothiazole ring, and an amide group. These structural features enable it to specifically bind to RIPK1 and inhibit its activity.

TargetMol will be a Gold Sponsor of the prestigious 2024 Harvard Chinese Life Science Annual Symposium, taking place on September 14, 2024. This annual event brings together leading researchers, industry professionals, and innovators from the global life sciences community, with a focus on advancements in biomedical research, biotechnology, and pharmaceutical sciences.

Bortezomibis a 20S proteasome inhibitor (Ki = 0.6 nM) with antitumor activity, capable of inhibiting NF-κB, disrupting the cell cycle, and inducing apoptosis

LY294002(SF 1101) is a broad-spectrum PI3K inhibitor that inhibits PI3Kα, PI3Kδ, and PI3Kβ (IC50=0.5/0.57/0.97 μM). It is also a DNA-PK inhibitor (IC50=1.4 μM) and a CK2 inhibitor (IC50=98 nM), and it can induce apoptosis and autophagy.

Insulin (human) (Product No. T8221, CAS 11061-68-0) is a polypeptide hormone secreted by pancreatic β-cells, with hypoglycemic activity. It promotes glycogen synthesis, regulates blood glucose levels, and is a key compound in maintaining the body's blood sugar balance.

Gemcitabine is a common pyrimidine nucleoside analog antimetabolite and antitumor agent. It targets and inhibits DNA synthesis, leading to autophagy and apoptosis.The chemical formula of gemcitabine is C9H11F2N3O4. Its core structure includes fluorine groups (specifically difluoro modifications) and an amino group. These two functional groups determine gemcitabine's pharmacological activity and stability. The design and development of prodrugs based on the amino group is also a current hot research topic.